• KemPharm Inc., of North Liberty, Iowa, presented data at the International Conference on Opioids in Boston showing that the firm's pain drug candidate, KP201, has abuse-deterrent properties and has been shown to significantly limit narcotic exposure upon intranasal administration and intravenous injection.